Compare ICG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICG | EQ |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 89.4M |
| IPO Year | 2022 | 2018 |
| Metric | ICG | EQ |
|---|---|---|
| Price | $1.43 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $2.00 | ★ $8.56 |
| AVG Volume (30 Days) | 282.3K | ★ 296.0K |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $109.44 | N/A |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $1.16 |
| 52 Week High | $2.28 | $6.20 |
| Indicator | ICG | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 34.91 |
| Support Level | $1.41 | N/A |
| Resistance Level | $1.52 | $1.54 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 75.00 | 1.11 |
Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.